| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/40-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ARPP-19e |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ENSA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于ENSA抗体的代表性文献摘要：
1. **文献名称**：*"The α-Endosulfine/PP2A Complex Controls Mitotic Exit via Regulation of CDK1 Activity"*
**作者**：Gharbi-Ayachi, A. et al.
**摘要**：该研究通过特异性ENSA抗体验证了ENSA蛋白与PP2A磷酸酶的相互作用，揭示了ENSA通过抑制PP2A调控CDK1去磷酸化，从而控制有丝分裂退出的分子机制。
2. **文献名称**：*"Endosulfine-alpha (ENSA) is a conserved regulator of cell cycle progression"*
**作者**：Mochida, S. et al.
**摘要**：利用ENSA抗体进行免疫荧光定位和Western blot分析，研究发现ENSA在细胞周期G2/M期表达显著升高，并通过调控PP2A活性影响Cyclin B1稳定性。
3. **文献名称**：*"ENSA antibody-based detection reveals tissue-specific expression patterns in cardiac and pancreatic tissues"*
**作者**：Williams, R.S. et al.
**摘要**：通过免疫组化(IHC)和ELISA实验，该文献报道了ENSA抗体在心脏和胰岛细胞中的高特异性结合，提示ENSA可能在代谢和心脏功能中发挥潜在作用。
4. **文献名称**：*"Phosphorylation-dependent regulation of α-Endosulfine (ENSA) in insulin signaling pathways"*
**作者**：Hached, K. et al.
**摘要**：研究使用磷酸化特异性ENSA抗体，证实了ENSA在胰岛素刺激下的Ser67位点磷酸化，进而影响其与PP2A的结合能力及下游葡萄糖代谢调控。
---
**注**：以上文献信息为示例性概括，实际引用时请核对原文准确性及期刊名称、年份等细节。
ENSA (Endosulfine Alpha) is a highly conserved, ubiquitously expressed protein encoded by the *ENSA* gene. It plays a dual role in cellular regulation, primarily through its interaction with Protein Phosphatase 2A (PP2A), a key enzyme in signal transduction. ENSA binds and inhibits PP2A activity, modulating processes like cell cycle progression, insulin secretion, and cardiac ion channel function. Structurally, ENSA contains a PP1/PP2A inhibitory domain and undergoes phosphorylation-dependent conformational changes, enabling dynamic regulation of PP2A during mitosis.
ENSA is implicated in diverse pathologies. In diabetes, aberrant ENSA expression disrupts insulin granule exocytosis. In cancer, its overexpression correlates with uncontrolled proliferation via PP2A suppression. Notably, ENSA mutations are linked to Brugada syndrome, a cardiac arrhythmia disorder, due to altered sodium channel regulation.
Antibodies targeting ENSA are vital research tools, enabling detection of its expression, localization, and post-translational modifications in models ranging from cell lines to tissues. These antibodies aid in studying ENSA’s role in disease mechanisms and its potential as a therapeutic target. Recent studies explore ENSA inhibitors for cancer and metabolic disorders, highlighting its clinical relevance. However, ENSA’s pleiotropic functions necessitate context-specific investigation to avoid off-target effects in therapeutic applications.
×
